Our Team
Chad Brown
Interim Chief Executive Officer
Chad Brown joined TwinStrand Biosciences in September 2022 and serves as the Interim Chief Executive Officer. Chad has over 30 years of commercial experience in Diagnostics and Life Science tools. Prior to joining TwinStrand he was the Senior Vice President of Sales and Marketing at NanoString Technologies where he led the commercial team through a period of double-digit growth driven primarily by new disruptive and transformational technologies. He has also had leadership roles at QIAGEN, Roche, and Chiron Diagnostics. He graduated from the University of Kentucky with a B.S in Health Care Administration.
Jesse Salk MD PhD
Chief Scientific Officer, Founder, Board Member
Dr. Salk is a molecular biologist, clinical oncologist, and a cofounder of TwinStrand. He invented and developed TwinStrand’s core Duplex Sequencing Technology with colleagues at the University of Washington. Jesse has authored more than two-dozen peer-reviewed publications in cancer biology and genomics, and has more than 50 issued and pending patents. In addition to his executive and scientific leadership role at TwinStrand, Jesse is an Affiliate Clinical Faculty member at the University of Washington and Fred Hutchinson Cancer Research Center and sees cancer patients part time at the VA Puget Sound in Seattle. He is Board Certified in Medical Oncology and Internal Medicine. Jesse is a volunteer teacher in science and medicine for students from middle school through post-doctoral levels. He holds an MD/PhD with honors from the University of Washington and a BS in Biology Summa Cum Laude from Brandeis University.
Kissy (Karen) Dabbs JD
General Counsel and Corporate Secretary
Kissy Dabbs is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Kellie Bickel PhD
Senior Vice President, Intellectual Property and Corporate Strategy
Dr. Bickel is a doctoral-level scientist with nearly two decades of intellectual property experience. She works closely with our scientists and business teams to identify and develop key patent positions around our technology and to execute our patent strategy. Kellie has previously worked on nationally recognized legal teams at both Perkins Coie, LLP, and at the University of Washington, where she strategically created and managed patent portfolios for both start-ups and large, publicly traded companies. She holds a PhD in Molecular & Cellular Biology from the University of Washington and is a USPTO-registered patent agent.
Clint Valentine MS
Vice President of Data Science
Clint Valentine leads a diverse team of bioinformatics scientists, software engineers, and technology professionals. He is responsible for the software products that TwinStrand releases which leverage TwinStrand’s core Duplex Sequencing™ Technology as well as all analytical professional services and computational R&D activity. Clint studied at Northeastern University where he earned a BS in Biology, a BS in Environmental Science, and an MS in Bioinformatics prior to joining the Biological Engineering Department at MIT through the Essigmann Lab. Over the course of his career, he has developed innovative NGS methods that are currently disrupting the fields of genetic toxicology and cancer minimal residual disease monitoring. Clint is passionate about discoveries related to the early imitating events of cancer as well as modern software development and its utility for improving human health outcomes. He serves on national leadership committees for genetic toxicology and advises Northeastern University as a member of the Bioengineering Industrial Advisory Board.
Martha Weckel
Vice President, Commercial
Martha Weckel is a Commercial Executive with a proven track record of leading commercial functions to drive growth and profitability in life science companies. She has extensive experience specializing in developing, launching, and maximizing biotechnology products in both diagnostic and biopharmaceutical companies, CLIA reference laboratories, and start-up ventures. She was most recently at ChromaCode as the AVP, Oncology and Genomics and prior to that was the Head of Marketing at Epic Sciences, focusing on liquid biopsy oncology applications. She has experience in commercializing both FDA IVD and CE marked products in oncology. Martha is a proud member of Athena, an organization dedicated to advancing women in STEM through leadership development and serves as a mentor. Martha earned a Bachelor’s degree in Biology from Dartmouth College.
Board of Directors
Chad Waite
Chairman of the Board
Chad Waite leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
Steve Dow
Board Member
Steve Dow’s venture capital investments over the past 37 years have spanned a broad range of technologies and markets, from software to communications technology to life science. Steve has served as an advisor, mentor, and board member for a variety of companies, typically beginning at the concept or seed stage and continuing beyond their IPO. He served as Chairman of the Board at Alder Biopharmaceuticals (ALDR) from its inception until 2018. He is a board member at Dataminr and Digital Ocean. Steve was the founding board member at Citrix Systems (CTXS) from its inception in 1989 until 2015, when its annual revenue was $3B. He has also been an advisor to several departments at Stanford University and on the investment committee at Caltech.
S. Somasegar
Board Member
Soma is a Managing Director at Madrona Venture Group focusing on B2B and enterprise related start-ups. Soma invests across a wide variety of technology areas including machine learning / artificial intelligence, intelligent applications, next-generation cloud infrastructure, multi-sense user interfaces and robotic process automation. More recently, Soma has also been investing in companies at the intersection of life science and computer science where there is high potential for using data, ML and AI to accelerate innovation in this space. Prior to joining Madrona in 2015, Soma had a successful twenty-seven year long career with Microsoft where he most recently was Corporate Vice President of the Developer Division. Soma has long been an angel investor in a wide range of technology start-ups both in the U.S. and internationally.
Michael Pellini MD
Board Member
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Jesse Salk MD PhD
Chief Scientific Officer, Founder, Board Member
Dr. Salk is a molecular biologist, clinical oncologist, and a cofounder of TwinStrand. He invented and developed TwinStrand’s core Duplex Sequencing Technology with colleagues at the University of Washington. Jesse has authored more than two-dozen peer-reviewed publications in cancer biology and genomics, and has more than 50 issued and pending patents. In addition to his executive and scientific leadership role at TwinStrand, Jesse is an Affiliate Clinical Faculty member at the University of Washington and Fred Hutchinson Cancer Research Center and sees cancer patients part time at the VA Puget Sound in Seattle. He is Board Certified in Medical Oncology and Internal Medicine. Jesse is a volunteer teacher in science and medicine for students from middle school through post-doctoral levels. He holds an MD/PhD with honors from the University of Washington and a BS in Biology Summa Cum Laude from Brandeis University.
Scientific Advisors
Lawrence A. Loeb MD PhD
Co-founder, Scientific Advisor
Dr. Loeb’s research for more than 60 years has focused on human cancer. He is a scientific visionary, best known for the concept of a mutator phenotype in cancer, which is the principle that tumors form and evolve resistance to therapy by virtue of their tendency to acquire mutations at an accelerated rate. He has published extensively in the fields of molecular biology, biochemistry, fidelity of DNA replication, creation of artificial enzymes, and Duplex Sequencing. Dr. Loeb graduated from The City College of New York, received an MD degree from New York University, a Post-Doctoral fellowship at NIH, and a PhD from The University of California Berkeley. He is a professor in the Departments of Pathology and Biochemistry at the University of Washington where he served as director of the MD/PHD program for 23 years. He is past president of The American Association of Cancer Research, The Environmental Mutagen Society and a fellow of American Academy of Arts and Sciences.
Jerald Radich MD
Scientific Advisor
Dr. Radich is a Member of the Clinical Research Division, Director of the Molecular Oncology CLIA Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center. He is a Professor of Medicine in the Division of Medical Oncology at the University of Washington. Dr. Radich’s research laboratory focuses on the molecular biology of response, resistance, and progression in acute and chronic myeloid leukemia. His clinical Molecular Oncology Lab provides the molecular diagnostic support for many institutional, US Intergroup, international, and pharmaceutical trials. Some of his major scientific contributions over the past three decades include being among the first to document the prevalence and significance of mutations in the Ras/MAPK signaling pathway in acute myeloid leukemia and recognition of the importance of measurable residual disease in ALL, AML and CML. He was awarded the International CML Foundation Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring chronic myeloid leukemia (CML) in the developing world. A mere subset of his many past and present leadership roles include: Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, Inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, past member of the Board of Scientific Counselors of the NIH Genome Research Institute, past-chair of the CML Committee of the National Comprehensive Cancer Network and current member of the European Leukemia Network CML committee. He serves on the Scientific Board of the International CML Foundation and the Max Foundation and leads the Laboratory Committee of the NCI AML Precision Medicine Initiative and the Foundation of the NIH’s program in measurable residual disease in AML. Dr. Radich holds a BS with Honors in Biology from UC San Diego, an MS in Epidemiology from Harvard University School of Public Health, and an MD from UC Davis School of Medicine.
